Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori"

Wednesday, October 23, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article provides an overview of the Instituto Romagnolo per lo Studio dei Tumori 'Dino Amadori', detailing its management structure, collaborations, patient studies, and pipeline of drug candidates. It highlights various ongoing studies, including those focused on lymphoma and leukemia, as well as the company's compassionate use policy. Additionally, it includes sections on investor relations and corporate governance.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 33 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are currently sponsored by Instituto Romagnolo?

Instituto Romagnolo sponsors studies on lymphoma, leukemia, and CLL.

What is the focus of the TakeAim studies?

The TakeAim studies focus on lymphoma, leukemia, and CLL treatments.

What drugs are included in the pipeline overview?

The pipeline includes Emavusertib, Fimepinostat, CA-170, and CA-327.

What is the compassionate use policy?

The compassionate use policy allows access to treatments for patients outside clinical trials.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Instituto Romagnolo lymphoma leukemia clinical studies
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →